JP2013520999A5 - - Google Patents

Download PDF

Info

Publication number
JP2013520999A5
JP2013520999A5 JP2012556250A JP2012556250A JP2013520999A5 JP 2013520999 A5 JP2013520999 A5 JP 2013520999A5 JP 2012556250 A JP2012556250 A JP 2012556250A JP 2012556250 A JP2012556250 A JP 2012556250A JP 2013520999 A5 JP2013520999 A5 JP 2013520999A5
Authority
JP
Japan
Prior art keywords
antibody
antibody fragment
seq
disease
der
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012556250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013520999A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/027094 external-priority patent/WO2011109662A1/en
Publication of JP2013520999A publication Critical patent/JP2013520999A/ja
Publication of JP2013520999A5 publication Critical patent/JP2013520999A5/ja
Pending legal-status Critical Current

Links

JP2012556250A 2010-03-04 2011-03-03 Ｃｄ５２に対するモノクローナル抗体 Pending JP2013520999A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31045010P 2010-03-04 2010-03-04
US61/310,450 2010-03-04
PCT/US2011/027094 WO2011109662A1 (en) 2010-03-04 2011-03-03 Monoclonal antibodies directed to cd52

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016130517A Division JP2017000142A (ja) 2010-03-04 2016-06-30 Ｃｄ５２に対するモノクローナル抗体

Publications (2)

Publication Number Publication Date
JP2013520999A JP2013520999A (ja) 2013-06-10
JP2013520999A5 true JP2013520999A5 (enExample) 2014-04-17

Family

ID=44531535

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012556250A Pending JP2013520999A (ja) 2010-03-04 2011-03-03 Ｃｄ５２に対するモノクローナル抗体
JP2016130517A Pending JP2017000142A (ja) 2010-03-04 2016-06-30 Ｃｄ５２に対するモノクローナル抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016130517A Pending JP2017000142A (ja) 2010-03-04 2016-06-30 Ｃｄ５２に対するモノクローナル抗体

Country Status (7)

Country Link
US (2) US8652470B2 (enExample)
EP (1) EP2542258A4 (enExample)
JP (2) JP2013520999A (enExample)
AU (2) AU2011223547B2 (enExample)
BR (1) BR112012022342A2 (enExample)
CA (1) CA2791866A1 (enExample)
WO (1) WO2011109662A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569460B2 (en) 2009-03-25 2013-10-29 Vet Therapeutics, Inc. Antibody constant domain regions and uses thereof
BR112012022342A2 (pt) 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais dirigidos a cd52
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
AU2012252153B2 (en) * 2011-05-06 2016-07-07 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparing and using the same
US9790280B2 (en) 2011-10-26 2017-10-17 Elanco Tiergesundheit Ag Monoclonal canine CD20 antibodies and methods of use
MX357655B (es) 2011-11-15 2018-07-18 Walter & Eliza Hall Inst Medical Res Mediador soluble.
AU2013344807B2 (en) * 2012-11-15 2018-05-24 The Walter And Eliza Hall Institute Of Medical Research Soluble mediator
CN105518018B (zh) * 2013-03-15 2020-04-03 细胞基因公司 修饰的t淋巴细胞
CA2932515C (en) 2013-12-20 2023-08-01 Intervet International B.V. Caninized antibodies
JP6673838B2 (ja) 2014-02-14 2020-04-01 セレクティスＣｅｌｌｅｃｔｉｓ 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞
ES2853823T3 (es) 2014-09-30 2021-09-17 Intervet Int Bv Anticuerpos de PD-L1 que se unen a PD-L1 canino
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
JP7008020B2 (ja) 2015-12-18 2022-01-25 インターベット インターナショナル ベー． フェー． ヒトおよびイヌｉｌ－４ｒアルファに対するイヌ化ヒト抗体
CA3187272A1 (en) 2020-10-08 2022-04-14 Thorsten Ross Trispecific binders
EP4376958A1 (en) 2021-07-30 2024-06-05 Affimed GmbH Duplexbodies
TW202334221A (zh) 2021-11-03 2023-09-01 德商安富美德有限公司 雙特異性cd16a結合劑
CN116785434A (zh) * 2023-03-29 2023-09-22 暨南大学附属第一医院（广州华侨医院） 一种cd52+巨噬细胞作为骨关节炎治疗靶点的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU640397B2 (en) 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
JP3919830B2 (ja) * 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3087696B2 (ja) 1997-07-25 2000-09-11 日本電気株式会社 分散メモリ型マルチプロセッサ・システム制御方法およびコンピュータ読み取り可能な記録媒体
US6573372B2 (en) 1999-01-07 2003-06-03 Heska Corporation Feline immunoglobulin E molecules and compositions there of
ATE365539T1 (de) 1999-12-30 2007-07-15 Dana Farber Cancer Inst Inc Proteoliposomen, die ein integral membranprotein mit einer oder memhreren transmembrandomänen enthalten
EP1268794A2 (en) 2000-04-07 2003-01-02 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
ES2384100T3 (es) 2001-12-03 2012-06-29 Alexion Pharmaceuticals, Inc. Método para producir anticuerpos híbridos
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
US7261890B2 (en) 2001-12-21 2007-08-28 Idexx Laboratories, Inc. Methods for using canine immunoglobulin variable domains and caninized antibodies
CN100522999C (zh) 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
CN1646161A (zh) * 2002-02-21 2005-07-27 杜克大学 自身免疫疾病的药剂和治疗方法
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
WO2004043344A2 (en) 2002-11-07 2004-05-27 Immunogen, Inc. Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
JP4804357B2 (ja) * 2003-11-01 2011-11-02 メルク パテント ゲーエムベーハー 改変抗ｃｄ５２抗体
WO2006007202A2 (en) * 2004-05-28 2006-01-19 Idexx Laboratories, Inc Canine cd20 compositions
AU2005277567A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
EP1883653A2 (en) * 2005-05-24 2008-02-06 Avestha Gengraine Technologies Pvt. Ltd. Recombinant method for the production of a monoclonal antibody to cd52 for the treatment of chronic lymphocytic leukemia
PL1919503T3 (pl) 2005-08-10 2015-04-30 Macrogenics Inc Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
US7951918B2 (en) 2006-03-17 2011-05-31 Biogen Idec Ma Inc. Stabilized polypeptide compositions
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
GB0707640D0 (en) 2007-04-20 2007-05-30 Strathclyde Acoustic deterrence
US8337842B2 (en) 2008-09-04 2012-12-25 Vet Therapeutics, Inc. Monoclonal antibodies
US8569460B2 (en) 2009-03-25 2013-10-29 Vet Therapeutics, Inc. Antibody constant domain regions and uses thereof
BR112012022342A2 (pt) 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais dirigidos a cd52
JP5911813B2 (ja) 2010-03-04 2016-04-27 ベット・セラピューティクス・インコーポレイテッドＶｅｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Ｃｄ２０に対するモノクローナル抗体

Similar Documents

Publication Publication Date Title
JP2013520999A5 (enExample)
JP2013520990A5 (enExample)
Cambridge et al. B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response
Kortlever et al. Myc cooperates with Ras by programming inflammation and immune suppression
Herrlinger et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
WO2011050106A3 (en) Anti-cd3 antibody dosing in autoimmune disease
JP2012121878A5 (enExample)
Pomés et al. 100 Years later: Celebrating the contributions of x-ray crystallography to allergy and clinical immunology
JP2020511123A5 (enExample)
UA105768C2 (uk) Антитіла до рецептора кінцевих продуктів глибокого глікування (rage) і їх застосування
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
JP2012254083A5 (enExample)
JO3764B1 (ar) جزيئات إرتباط il-18
DOP2013000129A (es) PROTEÍNAS DE UNIÓN AL TNF-a.
MX377475B (es) Anticuerpo monoclonal de interleucina-31.
BR112014000263A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico, e, composição farmacêutica
JO3097B1 (ar) الأجسام المضادة c-Met
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
BR112013028523A2 (pt) uso de um anticorpo ou uma proteína de fusão ou um fragmento de ligação da mesma e método para a purificação de um anticorpo, uma proteína de fusão ou um fragmento de ligação da mesma de uma mistura fonte
JP2011184466A5 (enExample)
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
JP2014503189A5 (enExample)
JP2013538057A5 (enExample)
BR112017027549A2 (pt) anticorpo para cd40
NZ629178A (en) Antibodies to matrix metalloproteinase 9